These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23665809)

  • 1. Alternative in vitro methods to characterize the role of Endocrine Active Substances (EASs) in hormone-targeted tissues.
    Rovida C; De Angelis I; Lorenzetti S
    ALTEX; 2013; 30(2):253-5. PubMed ID: 23665809
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there a need in regulatory toxicity testing for evaluating chemicals at doses eliciting general toxicity?
    Chahoud I; Grote K
    Toxicology; 2016 Jul; 363-364():46-7. PubMed ID: 27430607
    [No Abstract]   [Full Text] [Related]  

  • 3. A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids.
    Kolle SN; Ramirez T; Kamp HG; Buesen R; Flick B; Strauss V; van Ravenzwaay B
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):259-78. PubMed ID: 22554500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays.
    Benigni R; Bossa C; Tcheremenskaia O; Giuliani A
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):809-19. PubMed ID: 20438313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Courage for simplification and imperfection in the 21st century assessment of "Endocrine disruption".
    Dietrich DR
    ALTEX; 2010; 27(4):264-78. PubMed ID: 21240469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid hormone disruption.
    Scholz S; Renner P; Belanger SE; Busquet F; Davi R; Demeneix BA; Denny JS; Léonard M; McMaster ME; Villeneuve DL; Embry MR
    Crit Rev Toxicol; 2013 Jan; 43(1):45-72. PubMed ID: 23190036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity testing: the need for new maps for the future.
    Balls M
    Altern Lab Anim; 2011 Oct; 39(5):417-8. PubMed ID: 22103936
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrated decision-tree testing strategies for environmental toxicity with respect to the requirements of the EU REACH legislation.
    Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Oct; 36 Suppl 1():29-42. PubMed ID: 19025330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative approaches to vertebrate ecotoxicity tests in the 21st century: A review of developments over the last 2 decades and current status.
    Lillicrap A; Belanger S; Burden N; Pasquier DD; Embry MR; Halder M; Lampi MA; Lee L; Norberg-King T; Rattner BA; Schirmer K; Thomas P
    Environ Toxicol Chem; 2016 Nov; 35(11):2637-2646. PubMed ID: 27779828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food for thought...on alternative methods for chemical safety testing.
    Hartung T
    ALTEX; 2010; 27(1):3-14. PubMed ID: 20390236
    [No Abstract]   [Full Text] [Related]  

  • 11. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
    Browne P; Noyes PD; Casey WM; Dix DJ
    Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity.
    Hewitt M; Ellison CM; Enoch SJ; Madden JC; Cronin MT
    Reprod Toxicol; 2010 Aug; 30(1):147-60. PubMed ID: 20006701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race is on to find alternative to animal tests.
    Goodman S
    Nature; 2002 Jul; 418(6894):116. PubMed ID: 12110854
    [No Abstract]   [Full Text] [Related]  

  • 14. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal testing: more than a cosmetic change.
    Abbott A
    Nature; 2005 Nov; 438(7065):144-6. PubMed ID: 16281001
    [No Abstract]   [Full Text] [Related]  

  • 16. Uncertainty of testing methods--what do we (want to) know?
    Paparella M; Daneshian M; Hornek-Gausterer R; Kinzl M; Mauritz I; Mühlegger S
    ALTEX; 2013; 30(2):131-44. PubMed ID: 23665803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards an integrated in vitro strategy for repeated dose toxicity testing.
    Vanhaecke T; Pauwels M; Vinken M; Ceelen L; Rogiers V
    Arch Toxicol; 2011 May; 85(5):365-6. PubMed ID: 21512801
    [No Abstract]   [Full Text] [Related]  

  • 18. CAN'T FIND THE RHYTHM.
    Schoenfuss HL; Ward JL
    Integr Environ Assess Manag; 2018 Sep; 14(5):660-663. PubMed ID: 30489021
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimization and validation of a method to identify skin sensitization hazards using IL-1 α and IL-6 secretion from HaCaT.
    Jeon B; Kim MO; Kim YS; Han HY; Yun JH; Kim J; Huang Y; Choi Y; Cho CH; Kang BC; Kim S; Choi TH
    Toxicol In Vitro; 2019 Dec; 61():104589. PubMed ID: 31276782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of innovative technologies and strategies for regulatory safety assessment methods: challenges and opportunities.
    Stokes WS; Wind M
    ALTEX; 2010; 27(3):87-95. PubMed ID: 21113563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.